NASDAQ:NRIX Nurix Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $29.40 +0.99 (+3.48 %) (As of 09/25/2020 12:22 PM ET) Add Compare Share Today's Range$28.72Now: $29.40▼$29.5050-Day Range N/A52-Week Range$15.21Now: $29.40▼$37.46Volume1,676 shsAverage Volume263,447 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsHeadlinesSocial Media Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $36.00, Nurix Therapeutics has a forecasted upside of 23.8% from its current price of $29.07.Amount of Analyst CoverageNurix Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Community Rank Outperform VotesNurix Therapeutics has received 4 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNurix Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about Nurix Therapeutics and other stocks. Vote “Outperform” if you believe NRIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NRIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to grow in the coming year, from ($1.41) to ($1.13) per share. Previous Next Analyst Opinion: 2.5Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRIX Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees103 Outstanding Shares37,038,000Market Cap$1.09 billion Next Earnings DateN/A OptionableNot Optionable $29.40 +0.99 (+3.48 %) (As of 09/25/2020 12:22 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive NRIX News and Ratings via Email Sign-up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Nurix Therapeutics (NASDAQ:NRIX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Nurix Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Nurix Therapeutics. What price target have analysts set for NRIX? 4 Wall Street analysts have issued 1 year target prices for Nurix Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they expect Nurix Therapeutics' share price to reach $36.00 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price. View analysts' price targets for Nurix Therapeutics. Who are some of Nurix Therapeutics' key competitors? Some companies that are related to Nurix Therapeutics include Change Healthcare (CHNG), SmileDirectClub (SDC), Vir Biotechnology (VIR), MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), MorphoSys (MOR), Evotec (EVTCY), Wright Medical Group (WMGI), Neogen (NEOG), BTG (BTGGF), NeoGenomics (NEO), FibroGen (FGEN), ICU Medical (ICUI), Integra Lifesciences (IART) and Allakos (ALLK). View all competitors. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include AbbVie (ABBV), Datadog (DDOG), Docusign (DOCU), Fastly (FSLY), JPMorgan Chase & Co. (JPM), Lovesac (LOVE), NIO (NIO), Overstock.com (OSTK), Pinduoduo (PDD) and Shopify (SHOP). Who are Nurix Therapeutics' key executives? Nurix Therapeutics' management team includes the following people: Dr. Arthur T. Sands, CEO, Pres & Director (Age 58, Pay $1.13M)Dr. Gwenn Hansen Ph.D., Chief Scientific Officer (Age 49, Pay $601.55k)Dr. Pierre Beaurang, Chief Bus. Officer (Age 50, Pay $597.67k)Dr. John Kuriyan, FounderDr. Michael Rapé Ph.D., Founder When did Nurix Therapeutics IPO? (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. What is Nurix Therapeutics' stock symbol? Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX." When did Nurix Therapeutics' quiet period expire? Nurix Therapeutics' quiet period expired on Wednesday, September 2nd. Nurix Therapeutics had issued 11,000,000 shares in its public offering on July 24th. The total size of the offering was $209,000,000 based on an initial share price of $19.00. During Nurix Therapeutics' quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. How do I buy shares of Nurix Therapeutics? Shares of NRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nurix Therapeutics' stock price today? One share of NRIX stock can currently be purchased for approximately $29.40. How big of a company is Nurix Therapeutics? Nurix Therapeutics has a market capitalization of $1.09 billion. Nurix Therapeutics employs 103 workers across the globe. This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
